Skip to main
CRNX

CRNX Stock Forecast & Price Target

CRNX Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 73%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Crinetics Pharmaceuticals Inc. has demonstrated a strong upward revision in revenue estimates for its lead product, Paltusotine, with projections for 2026 rising to approximately $100 million from a previous estimate of $43 million, highlighting robust demand and pricing strength. The company reported over $5 million in net product revenue for Paltusotine in 4Q25, exceeding prior estimates and underscoring stronger-than-expected sales performance. Furthermore, the early positive responses from patients, with symptom improvement within the first 2-4 weeks of treatment, create a favorable outlook for patient adoption and sustained revenue growth as the company progresses through its developmental milestones.

Bears say

Crinetics Pharmaceuticals faces significant challenges that contribute to a negative outlook on its stock, primarily centered around financial and commercial viability concerns. The company is projected to incur net losses until at least the commercialization phase, indicating ongoing financial strain and uncertainty. Additionally, potential obstacles to commercial uptake exist due to the lack of differentiation of its products from existing therapies, compounded by recent reductions in peak sales estimates that reflect a more cautious market approach.

CRNX has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 73% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Crinetics Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Crinetics Pharmaceuticals Inc (CRNX) Forecast

Analysts have given CRNX a Buy based on their latest research and market trends.

According to 11 analysts, CRNX has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $83.27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $83.27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Crinetics Pharmaceuticals Inc (CRNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.